Sanz-Cuesta T, Gonzlez-Escobar P, Riesgo-Fuertes R, Garrido-Elustondo S, del Cura-Gonzlez I, Martn-Fernndez J, Escortell-Mayor E, Rodrguez-Salvans F, Garca-Solano M, Gonzlez-Gonzlez R, Martn-de la Sierra M
For the older patients (60+ years) specially with arteriosclerosis, possibility of circulatory collapse after administration should be kept in mind (30)
Any AHK-Cu timeline inherits that biology: the mechanism is real, but it's a multi-month mechanism
Early trials show significant weight loss and metabolic improvements
The following subsections cover ideal candidates for maintenance dosing and diagnosed deficiency treatment
Lean subjects: low NNMT activity in adipose tissue